| NEONAX (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer: - A prospective, randomized, controlled, phase II study of the AIO Pancreatic Cancer Group |
|
|
|
Abstract |
2015 |
|
Pankreaskarzinom
|
|
|
|
|
|
| Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group (AIO-LQ-0111) |
|
|
|
Vollpublikation |
2015 |
|
Lebensqualität und PRO
|
|
|
| ascopubs.org/doi/10.1200/JCO.2014.60.4587 |
|
|
| Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial |
|
|
|
Vollpublikation |
2015 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| linkinghub.elsevier.com/retrieve/pii/S1470-2045(15)00042-X |
|
|
| Intraperitoneal bevacizumab (bev) for control of malignant ascites due to advanced-stage gastrointestinal cancers (GI): A multicentre double-blind, placebo (pl)-controlled, randomized phase II study. AIO-SUP-0108 |
|
|
|
Abstract |
2014 |
|
Supportive Therapie
|
|
|
| academic.oup.com/annonc/article/25/suppl_4/iv520/2242245 |
|
|
| NEONAX (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer: - A phase II study of the AIO Pancreatic Cancer Group |
|
|
|
Abstract |
2014 |
|
Pankreaskarzinom
|
|
|
| ascopubs.org/doi/10.1200/jco.2015.33.3_suppl.tps497 |
|
|
| HER-FLOT: Trastuzumab in combination with FLOT (infusional 5-fluorouracil [5-FU], leucovorin,oxaliplatin, and docetaxel) as perioperative treatment for patients (pts) with HER-2 positive locally advanced esophagogastric adenocarcinoma (EGA): a phase II trial of the AIO gastric cancer study group (AIO-STO-0310) |
|
|
|
Abstract |
2014 |
|
Ösophagus-/Magenkarzinome
|
|
|
|
|
|
| Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212). |
|
|
| Int J Cancer 154 (5): 863-72 |
|
2014 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1002/ijc.34760 |
|
|
| Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207) |
|
|
|
Abstract |
2014 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
|
|
|
| Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment |
|
|
|
Abstract |
2013 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.3586 |
|
|
